ConductScience.org, home

Paper37985191

Management of locally advanced non-small cell lung cancer: State of the art and future directions.

Miao D and 7 others. Cancer Commun (Lond), 2024. Cited by 148 papers, by iCite.

Cite this record

ConductScience Library. Management of locally advanced non-small cell lung cancer: State of the art and future directions. Papers, record 37985191. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37985191

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Management of locally advanced non-small cell lung cancer: State of the art and future directions.
PubMed
Journal
Cancer Commun (Lond)
PubMed
Year
2024
PubMed
Publication types
Journal Article, Review, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
148
iCite
Relative citation ratio, by iCite
20.71, provisional
iCite
Revised in PubMed
2026-09-22
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Miao DDa
2Zhao JJing
3Han YYing
4Zhou JJiaqi
5Li XXiuzhen
6Zhang TTing
7Li WWen
8Xia YYanghttps://orcid.org/0000-0003-2487-2244

Source PubMed

Download CSV of authors

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Carcinoma, Non-Small-Cell LungMajor topic
Lung NeoplasmsMajor topic
Humans
Neoplasm Staging
Combined Modality Therapy
Prognosis

References118

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
126275735Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial.Lancet2015https://conductscience.org/library/papers/26275735PubMed
219632716Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial.Lancet2009https://conductscience.org/library/papers/19632716PubMed
337985191Management of locally advanced non-small cell lung cancer: State of the art and future directions.Cancer Commun (Lond)2024https://conductscience.org/library/papers/37985191PubMed
432161398Inflammatory microenvironment remodelling by tumour cells after radiotherapy.Nat Rev Cancer2020https://conductscience.org/library/papers/32161398PubMed
536720083Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.J Clin Oncol2023https://conductscience.org/library/papers/36720083PubMed
628885881Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.N Engl J Med2017https://conductscience.org/library/papers/28885881PubMed
739173098Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR-Mutant, Metastatic Nonsquamous Non-Small Cell Lung Cancer.J Clin Oncol2024https://conductscience.org/library/papers/39173098PubMed
831445730Treatment of Nivolumab Results in Hyperprogressive Disease in a Patient Harboring EGFR Exon 20 Insertion and MYC Amplification.J Thorac Oncol2019https://conductscience.org/library/papers/31445730PubMed
928899864Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling.Cancer Discov2017https://conductscience.org/library/papers/28899864PubMed
1034290408Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers.Nature2021https://conductscience.org/library/papers/34290408PubMed
1116015535Non-small cell lung cancer therapy-related pulmonary toxicity: an update on radiation pneumonitis and fibrosis.Semin Oncol2005https://conductscience.org/library/papers/16015535PubMed
1214662433Excisional surgery for cancer cure: therapy at a cost.Lancet Oncol2003https://conductscience.org/library/papers/14662433PubMed
1328727865Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Final Results of a Phase 2 Study.JAMA Oncol2017https://conductscience.org/library/papers/28727865PubMed
1434251873SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial.J Clin Oncol2021https://conductscience.org/library/papers/34251873PubMed
1531194613Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study.J Clin Oncol2019https://conductscience.org/library/papers/31194613PubMed
1632469385
Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-up.
JAMA Oncol2020https://conductscience.org/library/papers/32469385PubMed
178043059A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer.N Engl J Med1994https://conductscience.org/library/papers/8043059PubMed
1837013636A novel transcriptional signature identifies T-cell infiltration in high-risk paediatric cancer.Genome Med2023https://conductscience.org/library/papers/37013636PubMed
1934116229Gefitinib With Concurrent Thoracic Radiotherapy in Unresectable Locally Advanced NSCLC With EGFR Mutation; West Japan Oncology Group 6911L.J Thorac Oncol2021https://conductscience.org/library/papers/34116229PubMed
2019861907Preoperative versus postoperative chemotherapy in patients with resectable non-small cell lung cancer: systematic review and indirect comparison meta-analysis of randomized trials.J Thorac Oncol2009https://conductscience.org/library/papers/19861907PubMed

See all 118 referencesDownload CSV of references

Cited by122

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 148 citations.

PMIDTitleJournalYearIn PapersSource
42959600Shining a Light on the Mechanisms of Drug Resistance to Anti-PD-1 Therapy in Non-small Cell Lung Cancer.Hum Mutat2026https://conductscience.org/library/papers/42959600PubMed
42919317ERK/GATAD2A/SAA1 axis drives osimertinib resistance via NF-κB and macrophage reprogramming in EGFR-mutated lung adenocarcinoma.J Exp Clin Cancer Res2026https://conductscience.org/library/papers/42919317PubMed
42870959Synergistic effects and molecular mechanisms of pirfenidone combined with EGFR-TKIs in non-small cell lung cancer.Transl Lung Cancer Res2026https://conductscience.org/library/papers/42870959PubMed
42771098ProtoSurv: prototype-guided adaptation of computed tomography foundation model for lung-cancer prognosis prediction.Vis Comput Ind Biomed Art2026https://conductscience.org/library/papers/42771098PubMed
42724680Pathological role of deubiquitinating enzymes in lung cancer: recent insights and advances.Am J Cancer Res2026https://conductscience.org/library/papers/42724680PubMed
42724255Development of clinical-radiological prediction models to prioritize ALK, ROS1, and RET fusion testing in major driver alteration-negative non-small cell lung cancer.J Thorac Dis2026https://conductscience.org/library/papers/42724255PubMed
42723745Predictive modeling of peripheral blood EGFR positivity in patients with advanced primary non-small cell lung cancer.Transl Lung Cancer Res2026https://conductscience.org/library/papers/42723745PubMed
42630367
Alterations in peripheral blood inflammatory mediators, vascular endothelial growth factor, and serum tumor markers in advanced non-small cell lung cancer patients treated with bevacizumab combined with chemotherapy.
Am J Transl Res2026https://conductscience.org/library/papers/42630367PubMed
42591560Clinical overall survival prediction and disease characteristics of locally advanced non-small cell lung cancer: an integrated analysis based on the SEER and TCGA databases.Transl Cancer Res2026https://conductscience.org/library/papers/42591560PubMed
42583196Machine learning models predict survival in unresectable stage III non-small cell lung cancer: Surveillance, Epidemiology, and End Results and Chinese cohort study.J Thorac Dis2026https://conductscience.org/library/papers/42583196PubMed
42559326Calcium Phosphate Nanoparticle Delivery of siTRIB3 Inhibits EMT and Stemness in NSCLC.Int J Nanomedicine2026https://conductscience.org/library/papers/42559326PubMed
42524437Integrative bulk and single-cell transcriptomic analysis identify an ac4C-related signature in lung adenocarcinoma.J Cancer2026https://conductscience.org/library/papers/42524437PubMed
42505209Prognostic Impact of the Systemic Immune-Inflammation Index According to Concurrent Chemotherapy Backbone in Stage III Non-Small Cell Lung Cancer.Curr Oncol2026https://conductscience.org/library/papers/42505209PubMed
42453889Effectiveness and safety of carbon ion radiotherapy for stage III non-small cell lung cancer: a single-center retrospective study.Front Oncol2026https://conductscience.org/library/papers/42453889PubMed
42449581
Efficacy and Time-Dependent Pattern of Consolidation Immunotherapy in Stage III Non-Small Cell Lung Cancer After Induction Chemoimmunotherapy and Radiotherapy: A Dual-Center Retrospective Cohort Study.
Cancers (Basel)2026https://conductscience.org/library/papers/42449581PubMed
42366402From metabolic to pathologic complete response: case report of Neoadjuvant Lorlatinib in Stage IIIB ALK-positive NSCLC combined with uniportal VATS.J Cardiothorac Surg2026https://conductscience.org/library/papers/42366402PubMed
42365360Risk modifiers of immune-related adverse events in patients with NSCLC undergoing immunotherapy: a retrospective cohort study.J Pharm Health Care Sci2026https://conductscience.org/library/papers/42365360PubMed
42361687S100A10 promotes tumorigenesis and metastasis in lung adenocarcinoma by regulating JUND/TNC axis-mediated EMT.Transl Oncol2026https://conductscience.org/library/papers/42361687PubMed
42321727Body composition radiomics integrated with machine learning to predict prognosis in advanced NSCLC treated with first-line immunochemotherapy and concurrent radiotherapy.BMC Pulm Med2026https://conductscience.org/library/papers/42321727PubMed
42318455Safety profile of ipilimumab in elderly patients: a disproportionate analysis based on the FDA Adverse Event Reporting System database.Front Oncol2026https://conductscience.org/library/papers/42318455PubMed

See all 122 cited byDownload CSV of cited by

Genes29

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ALK238PubTator's text mininghttps://conductscience.org/library/genes/238NCBI Gene
BRAF673PubTator's text mininghttps://conductscience.org/library/genes/673NCBI Gene
CCL36348PubTator's text mininghttps://conductscience.org/library/genes/6348NCBI Gene
CD27429126PubTator's text mininghttps://conductscience.org/library/genes/29126NCBI Gene
CD8A925PubTator's text mininghttps://conductscience.org/library/genes/925NCBI Gene
CDK41019PubTator's text mininghttps://conductscience.org/library/genes/1019NCBI Gene
CTLA41493PubTator's text mininghttps://conductscience.org/library/genes/1493NCBI Gene
EGFR1956PubTator's text mininghttps://conductscience.org/library/genes/1956NCBI Gene
ENTPD1953PubTator's text mininghttps://conductscience.org/library/genes/953NCBI Gene
FAS355PubTator's text mininghttps://conductscience.org/library/genes/355NCBI Gene
GZMK3003PubTator's text mininghttps://conductscience.org/library/genes/3003NCBI Gene
HAVCR284868PubTator's text mininghttps://conductscience.org/library/genes/84868NCBI Gene
IL7R3575PubTator's text mininghttps://conductscience.org/library/genes/3575NCBI Gene
KLRC13821PubTator's text mininghttps://conductscience.org/library/genes/3821NCBI Gene
LAG33902PubTator's text mininghttps://conductscience.org/library/genes/3902NCBI Gene
MYC4609PubTator's text mininghttps://conductscience.org/library/genes/4609NCBI Gene
NKX2-17080PubTator's text mininghttps://conductscience.org/library/genes/7080NCBI Gene
NT5E4907PubTator's text mininghttps://conductscience.org/library/genes/4907NCBI Gene
PDCD15133PubTator's text mininghttps://conductscience.org/library/genes/5133NCBI Gene
RB15925PubTator's text mininghttps://conductscience.org/library/genes/5925NCBI Gene

See all 29 genesDownload CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/37985191

GET https://conductscience.org/api/papers/v1/37985191/references?page=2